CEO Geert Kersten Summarizes CEL-SCI's Phase 3 Cancer Immunotherapy Progress in a New Video Interview
February 23 2016 - 8:00AM
Business Wire
CEL-SCI Corporation (NYSE MKT:CVM) announced today that a
new video interview with Geert Kersten, Chief Executive Officer, is
available for viewing. This new video summarizes CEL-SCI’s Phase 3
head and neck cancer trial progress and responds to questions about
the ongoing $50 million plus arbitration that CEL-SCI brought
against its former Clinical Research Organization (CRO). The
arbitration hearing (“trial”) has been scheduled to start in spring
of 2016.
The interview was conducted at the Source Capital 2016
Disruptive Growth & Healthcare Conference with Stock News Now
and is available to view at
https://www.youtube.com/watch?v=lQ8DnD6Uz3E or on CEL-SCI’s website
at www.cel-sci.com/investor_relations.html.
This new video is different from last week’s video in which Mr.
Kersten was a guest on Fox Business’ ‘Making Money with Charles
Payne’. The segment, which focused on finding a cure to cancer,
aired on Wednesday, February 17 between 6:00 and 7:00 p.m. ET. To
view the segment, please visit:
http://video.foxbusiness.com/v/4761247378001/are-scientists-on-the-cusp-of-finding-a-cure-for-cancer/?#sp=show-clips
About CEL-SCI Corporation
CEL-SCI is a Phase 3 immunotherapy company with platform
technologies that can potentially treat a variety of cancers and
viral diseases. We believe that one must activate the immune system
BEFORE radiation and chemotherapy, and even before surgery, to
achieve the best results in the greatest number of patients.
CEL-SCI is conducting a Phase 3 trial in 24 countries of Multikine
(Leukocyte Interleukin Injection) for the treatment of head and
neck cancer, which accounts for about 6% of cancers globally and a
$6 billion market. Almost 700 patients are already enrolled in this
study. CEL-SCI is also testing Multikine with the U.S. Navy in HIV
infected patients with HPV related diseases. CEL-SCI has
development partnerships with Teva Pharmaceuticals, Orient
EuroPharma of Taiwan, Ergomed and the NIH. The Company operates its
own 75,000 sq. ft. manufacturing facility and produces Multikine
for its clinical trials. When fully built out, this facility will
have the capacity to supply about $3 billion worth of Multikine
annually. CEL-SCI is also developing its pre-clinical L.E.A.P.S.
(Ligand Epitope Antigen Presentation System) technology as a
potential vaccine for the treatment of rheumatoid arthritis.
The Company has operations in Vienna, Virginia, and in/near
Baltimore, Maryland.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160223005703/en/
CEL-SCI CorporationGavin de Windt, 703-506-9460
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Apr 2023 to Apr 2024